公司資料
Savara, Inc. 股價、新聞與催化劑
- 股票代碼:
- SVRA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.56 USD (-0.54%)
收盤價
最後更新: 2026年8月24日
1.08B USD
市值
股價為何變動
As of Aug 24, 2026, SVRA closed down 0.54% at $5.56. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Savara is a respiratory company focused on rare lung disease and inhaled therapies. Its story is built around severe pulmonary conditions with limited treatment options.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Savara sits in specialty biopharma.
商業模式特徵
The company depends on clinical data, inhaled-delivery execution, and the ability to build a rare-respiratory franchise.
生技產業定位
Savara is a niche respiratory biotech whose stock is tightly linked to trial and regulatory progress.
未來催化劑
- Savara’s next catalyst is MOLBREEVI in autoimmune pulmonary alveolar proteinosis, with regulatory and launch-readiness steps doing most of the work. The key question is whether the program can keep moving toward a real rare-disease commercial opportunity.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。